Clinical trials recruiting in Chambray-lès-Tours, France

Phase breakdown

Conditions recruiting in Chambray-lès-Tours, France

Recruiting trials in Chambray-lès-Tours, France

• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
  NCT07647328 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06588855 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819891 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
  NCT06764693 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk
  NCT07187726 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate Control
  NCT06833138 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  NCT07207811 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
  NCT07087054 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
  NCT06427304 · Phase: Not specified · Ages: 80 Years and older · Sex: All (male and female)
• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
  NCT07237256 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• DESTINY Breast Respond HER2-(Ultra)Low Europe
  NCT05945732 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation
  NCT07462910 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea
  NCT04937309 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
  NCT05512364 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
  NCT05116475 · Phase: Phase 3 · Ages: 18 Years to 120 Years · Sex: Male
• Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)
  NCT04075084 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• PRostate Olaparib Real World Evidence Study
  NCT06031805 · Phase: Not specified · Ages: 18 Years and older · Sex: Male
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
  NCT05232916 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
  NCT06207981 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator
  NCT06543173 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  NCT00271180 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
  NCT07124858 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study)
  NCT07499661 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• REBECCA Real-world Early BrEast CanCer mAnagement
  NCT06856343 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer
  NCT07661927 · Phase: Phase 2 · Ages: 60 Years and older · Sex: Female
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
  NCT06865105 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
  NCT06937905 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
  NCT06505018 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Chambray-lès-Tours, France?

33 recruiting trials have at least one study site in Chambray-lès-Tours, France.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.